Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This commentary proposes solutions for more rational reporting of serious adverse events in academic critical care trials to avoid inappropriate alarm and reduce unnecessary administrative burden.
Although it might be ideal to have a single system for defining and reporting serious adverse events that would be applicable to both academic trials investigating established drugs and industry-sponsored trials of novel pharmaceutical agents, such a system would be unlikely to satisfy all
No takes yet. Share an insight, caveat, or question.
Lauzier et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: